GlobeNewsWire
06 Aug 2026, 21:38 UTC · 6w ago
Verdict
Headline takes no side. We score BSEM +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
BioStem Technologies has been approved by Nasdaq to uplist its common stock from the OTC market to the Nasdaq Capital Market.
More positive than 92% of claims this week
Trading of BioStem Technologies (BSEM) on the Nasdaq is expected to commence on August 7, 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 62% of claims this week
The company expects the uplisting to expand its access to capital and improve its ability to attract talent.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company is uplisting from OTC to Nasdaq, which is expected to improve liquidity, visibility, and access to capital.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3d ago
+17.9%
Price agrees with the score
$4.74 vs $4.02 close before publication (Aug 6) · not market-adjusted
BSEM chart →
